Isoleucine, a branched-chain amino acid (BCAA), suppressed the development of NAFLD among obese youth by reducing the ability of insulin on hepatic glucose production in adiposity (Perng et al., 2014; Butte et al., 2015; Tricò et al., 2017). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.